Product Description: DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
Applications: Cancer-programmed cell death
Formula: C8H19ClN2O3S
Citations: Redox Biol. 2025 Feb 25:81:103567./Adv Sci (Weinh). 2023 Jun 17;e2206798./Algal Res. 2025 Mar./Biochem Biophys Res Commun. 2024 Jul 23:733:150436./Biochem Genet. 2024 Sep 24./Cell Death Dis. 2025 Mar 20;16(1):193./Cell Signal. 2025 Jan 3:111583./Ecotoxicol Environ Saf. 2022 Dec 1;247:114263./Ecotoxicol Environ Saf. 2022, 247: 114263./Eur J Med Chem. 2023 Nov 28, 115997./FASEB J. 2024 Jul 31;38(14):e23844./Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8./J Invest Dermatol. 2024 Dec 24:S0022-202X(24)03027-6./Med Oncol. 2023 Apr 10;40(5):141./Mol Cell Biochem. 2021 Jan 8./Nat Commun. 2024 Aug 30;15(1):7522./Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123./Res Sq. 2024 Sep 12:rs.3.rs-5065904./Research Square Preprint. 2023 May 24./Research Square Print. 2023 Mar 24./Small. 2021 Nov 1;e2103984.
References: [1]Griffith OW, et al. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979 Aug 25;254(16):7558-60./[2]Vanhoefer U, et al. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2(12):1961-8.
Molecular Weight: 258.77
Compound Purity: 99.09
Research Area: Cancer
Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 100 mg/mL (ultrasonic)
Target: Ferroptosis
Deutsch
English
